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New Universal Deﬁnition of Myocardial Infarction
Global Implications, Applicability, and Need for Flexibility
Jagdish C. Mohan *,, Jagat Narula 
New Delhi, India; and New York, NY, USAMyocardial infarction (MI) is a pathological
process but a clinical entity. For a pathologist, the
presence of myocardial necrosis is fundamental to
the detection of MI, but a clinician is usually fortu-
nate to detect this condition in the living. Ideally,
MI has to have ischemic source of injury, and for
want of deﬁnite evidence of ischemia, clinical diag-
nosis of MI always remains presumptive and indi-
rect. There are mimickers and associated comor-
bidities, which introduce uncertainty in diagnosis.
Hence, early, accurate, and consistent diagnosis of
MI remains a challenge despite discovery of
cardiomyocyte-speciﬁc biomarkers. Elevated levels
of troponin indicate myocardial injury, but not the
mechanism of injury. Although uniform availability
of the means to detect and deﬁne MI across the
globe remains a challenge, the deﬁnition has impli-
cations for epidemiology, disease monitoring,
content of registries, clinical research studies, clinical
trials, quality assurance, economic analysis, medico-
legal disputes, and estimation of healthcare costs [1].
H I S TO R I C A L A S P E C T S
Although the crude description of MI has been
available for centuries, an exponential growth in its
understanding, knowledge, and management has
occurred only in the twentieth century. James B.
Herrick, a Chicago internist, presented the ﬁrst
detailed description of non-fatal acute MI in 1912
[2]. However, a couple of years earlier, Obratzow
and Straches (1910) had distinguished the clinical
entity of coronary thrombosis from that of angina
pectoris [3]. Parkinson and Bedford believed that
coronary thrombosis was diagnosed in 1878 byJ.C.M. is the section editor for the Global Intelligence section of Global Hea
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term myomalacia cordis [4]. However, a simple,
clinically useful and robust deﬁnition of MI eluded
clinicians long after the initial description. Deﬁni-
tion of MI evolved over time with emphasis shifting
from clinical presentation to electrocardiographic
changes to the release of intracardiomyocytic macro-
molecules. The latter macromolecules are generally
water-soluble and hence wash out because myocyte
necrosis is accompanied by the loss of integrity of
sarcolemma. Intramyocardial enzymes (including
transaminases) and fragments of contractile protein
apparatus (such as myoglobin, light chains of
myosin, troponins) have been traditionally measured
as the indicators of the severity of myocyte necrosis.
Measurement of the cardiac troponins (or cTn, I,
and T) offers high speciﬁcity and reproducibility,
and high sensitivity assays accord high negative
predictive value to the test [5,6]. Although highly
sensitive and speciﬁc, myocardial injury with release
of contractile apparatus proteins in circulation can be
secondary to a variety of pathobiological processes;
central to this theme is the presence of the clinical
picture of myocardial ischemia. It is somewhat difﬁ-
cult to establish this relationship when one is dealing
with sick and old patients with multiple comorbid-
ities, and also following the procedures wherein the
heart is manipulated. Hence, the introduction and
perpetuation of the rise and/or fall of cardiac
biomarkers above the 99th percentile of upper refer-
ence limits (URL) in this new deﬁnition is similar to
the previous version of the Global MI task Force
[7,8]. Is the new deﬁnition able to be generalized
and what are its implications for low- and middle-
income countries (LMIC)?rt.
a; Michael A. Weiner Cardiovascular Institute of the Mount Sinai School
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Broadly, the criteria have remained unchanged
except for the diagnosis of procedure-related MI.
As the new universal deﬁnition states, “the diagnosis
of acute MI is a clinical diagnosis based on patient
symptoms, ECG changes, and highly sensitive
biochemical markers, as well as information gleaned
from various imaging techniques” [8]. There is
unlikely to be any major disagreement with regard
to clinical and electrocardiographic criteria, which
are essentially supportive rather than diagnostic.
Use of any imaging technique for quick detection
of MI shall remain limited because of unacceptable
delay in conducting and interpreting any of the avail-
able tests. The key question in acute myocardial
infarction is how to determine the evidence of
myocardial necrosis in a clinical setting consistent
with myocardial ischemia. Herein comes the pivotal
role of the cardiac biomarkers (read as troponins).
The key point of the Third Universal Deﬁnition of
MI [8] is the detection of a rise and/or fall of cardiac
biomarker values, with at least one of the values being
elevated above the 99th percentile of upper reference
limit for a particular assay. The minor increase in
troponin previously called troponin disease or
troponin bump has become all-important for the
diagnosis of MI in the presence of myocardial
ischemia. The improved assay sensitivity and preci-
sion has allowed the detection of the trace quantities
of the troponin and hence allowed the detection of
many undetected micro-infarcts. The latest deﬁni-
tion makes it obligatory to test cardiac biomarkers
at least twice to detect rising or falling levels before
MI is diagnosed. By default, point-of-care bedside
troponin tests, which are read as positive or negative,
lose relevance for diagnosis of MI even if these are
highly sensitive but may have prognostic value for
a variety of conditions. However, quantitative
point-of-care ﬁnger-stick tests, which have relevance
in ER and primary care settings still may be useful.S PONTAN EOUS M I
Spontaneous MI, both type 1 and type 2, are the
dominant occurrences in all societies. Pertinent ques-
tions, which the new deﬁnition raise have important
implications for the developing world. The following
points need emphasis and clariﬁcation:
1. It is imperative for every facility managing MI to
have its own reference values so that there is clarityabout the 99th percentile URL. Obviously, it will
vary with the types of assay and the biomarker.
2. The point-of-care strip tests, which were read as
positive or negative for cardiac troponin are meant
for diagnosis but not for prognosis. However, in
subjects with high pre-test probability of thrombotic
coronary heart disease, single point-of-care tests may
be accurate and useful in the situation of insufﬁcient
resources.
3. The deﬁnition implies that the cardiac biomarkers
be tested twice or more to detect rising or falling
trends.
4. In patients with suspected acute coronary syndrome
who ﬁnally end up in the catheter lab or in the oper-
ating room, the tests will obviously be done at least
three times; twice for making a diagnosis or risk strat-
iﬁcation and at least once again for the detection of
post-procedural complication.
5. We need to be certain that the dynamic troponin
changes are only due to MI. Other conditions such
as infection, arrhythmia, stress cardiomyopathy,
etc., may also be responsible for dynamic changes.
6. The deﬁnition may also increase the workload of
clinicians and introduce time delay, especially when
a MI is almost certainly based upon the ECG criteria.
7. Thenewdeﬁnition stillwouldnotdifferentiateMI from
Tako-tsubo cardiomyopathy, which may be encoun-
tered in nearly 5% of the patients presenting with ACS.
8. Other biomarkers (including total CK, CK-MB
activity, lactate dehydrogenase, aspartate amino-
transferase, etc.) are relatively non-speciﬁc and
have been deleted from the deﬁnition. Although
elimination of various tests brings uniformity to
the detection of MI universally, these tests have
been commonly employed in LMIC for lower cost
and easy availability. There will be a substantial lag
time before these tests are phased out in the LMIC.
9. There is also the matter of access, equity, and the
cost for the LMIC. Clinical decisions may be
more difﬁcult in resource-constrainted societies
wherein an exponential increase in acute coronary
events is being encountered. Making dynamic
changes in troponin levels mandatory for the detec-
tion of MI will widen disparities with regard to
treatment.
10. Local expertise would need to be augmented to
develop cheaper assays to increase greater use of
cardiac troponins in developing countries.
11. The incidence of MI is likely to rise with the newer
deﬁnition and high-sensitive assays of the troponins.
Including micro-infarcts in the deﬁnition will alter
the trends in case fatality rates and initially create
epidemiologic disparities.
12. The analytical sensitivity (lower detection limit) of
the troponin assays is likely to increase in the future.
This will detect still more micro-infarcts whose
signiﬁcance may be uncertain.
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tivity may still be useful in the LMIC in certain
situations.
P E R I - P ROC EDURA L M I
MI after percutaneous coronary interventions (PCI,
Type 4) and coronary artery bypass surgery
(CABG, Type 5) is more common than believed or
reported. There is unfavorable prognosis associated
with raised biomarkers in these patients. The diag-
nosis of MI, however, has important diagnostic-
coding, medico-legal, insurance, and quality-of-care
issues. Stent thrombosis following PCI as the cause
of MI is pretty much a uniformly agreed upon mat-
ter. With so many incidental and unintentional
phenomena causing myocardial ischemia, which can
and does occur during PCI, it is reasonable that
peri-procedural MI should receive adequate atten-
tion. The new deﬁnition has raised the bar from three
to ﬁve times URL of troponin levels so that unneces-
sary panic and worry on the part of both physicians
and patients can be decreased. Using the previous
deﬁnition, up to 24% of patients undergoing non-
emergent PCI had MI by troponin criteria [9].
However, estimation of troponin is not routine after
apparently uncomplicated elective PCI [10], espe-
cially in developing countries because of cost consid-
erations. Even in the developed world there is a trend
towards shorter hospital stay after elective PCI
(< 24 h). Monitoring troponins will identify those
patients who need to stay longer. The knowledge
that troponin elevations occur even after otherwise
uncomplicated procedures and are associated with
a 20% increase in long-term mortality has triggered
the need to deﬁne PCI-related MI separate from
troponin bump [11]. Such a deﬁnition will help in
monitoring efﬁcacy of therapy, quality and standard
of cardio-protection during the procedure, anddevelopment of newer techniques to reduce proce-
dural MI. However, to identify PCI-related MI, at
least one pre-procedure and one post-procedure
troponin estimation shall become mandatory in all
patients. In fact, to catch the peak troponin level,
more frequent testing may be required. Although
adding imaging to this difﬁcult diagnosis is a good
idea it would increase the cost.
Rise in troponin levels following CABG is
more common [12], possibly because of ischemia-
reperfusion injury pattern and hence the new deﬁni-
tion (10 times URL of troponin) is more stringent
with regard to type 5 MI. Nearly 21% of patients
have >80 times URL rise in troponin [13] when
cardiopulmonary bypass is used; myocardial injury
and hence troponin release may be less pronounced
in off-pump surgeries [14]. Because patients may be
sedated following CABG, ECG changes may not
be necessarily speciﬁc and imaging difﬁcult in these
situations; troponin release may play an important
role in type 5 MI. A recent study has demonstrated
a graded relationship between troponin rise and
mortality following CABG regardless of the
threshold [15]. Thus, one could argue for or against
more stringent troponin criteria for deﬁnition of MI
related to open heart surgery. Deleting CK-MB
from the deﬁnition is also questionable since there
is so much data relating CK-MB rise to interme-
diate and long-term mortality [15]. As troponin
levels below the threshold of MI also affect prog-
nosis, the purpose of deﬁning MI by using more
stringent criteria and dissociating it from prognosis
could be misleading.
Overall, more reasoning has gone into the revised
deﬁnition of MI. The biomarker cacophony has
been eliminated and the clinician has to talk only
in terms of troponins. Its impact on LMIC will
need careful evaluation. Also, MI related to cardiac
procedures would need greater emphasis and more
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